Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II double-blind study of alpelisib in pediatric and adult patients with PIK3CA-related overgrowth spectrum
CTR20213097Phase 2Active
- Sponsor
- Novartis
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in PIK3CA-related overgrowth spectrum (PROS) comparing Alpelisib with Placebo (2 arms). Primary endpoint: Response at Week 24 assessed by blinded independent review committee. Started Jul 2022; status: active.
02
Drugs
alpelisib
03
Conditions
PIK3CA-related overgrowth spectrum (PROS)
Beyond the preview
Go deeper on CTR20213097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20213097.